GAITHERSBURG, Md., Sept. 10,
2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd
(Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global
biopharmaceutical company dedicated to discovering, developing,
manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer, today
announced that it will hold an extraordinary general meeting of
shareholders (the "EGM") at 10:00
a.m., Beijing time, on
September 27, 2024, virtually via a
Zoom video conference call, for the purpose of considering and, if
thought fit, passing the proposed resolutions set forth in the
notice of EGM (the "Notice of EGM").
Instructions for accessing the video conference call are as
follows:
Zoom Meeting URL:
https://us06web.zoom.us/j/6195900008?pwd=OTEvOGtnNFVpaUdBUkdRRlp4Y0txUT09
Meeting ID: 619 590 0008
Passcode: 666666
The purpose of the EGM is for the Company's shareholders to
approve several resolutions in relation to regaining compliance
with the minimum bid price requirement set forth under Nasdaq
Listing Rule 5450(a)(1) prior to the expiration of the grace period
on October 21, 2024, including (i)
with effect from October 1, 2024, to
consolidate every 10 (ten) ordinary shares, par value of
US$0.00002 each (whether issued or
unissued), into 1 (one) ordinary share, par value of US$0.0002 each (the "Share Consolidation"); and
(ii) with effect immediately following the Share Consolidation, to
amend and restate the currently effective memorandum and articles
of association of the Company by their deletion in their entirety
and the substitution in their place of the second amended and
restated memorandum and articles of association of the Company.
The close of business on September 11,
2024 (Eastern Time) has been fixed as the record date of
the EGM. Holders of record of the Company's ordinary shares as
of the record date shall be entitled to attend and vote at the EGM
virtually and any adjourned meeting thereof. The Notice of EGM and
proxy card for the EGM are available on the Company's website at
investor.lakeshorebio.com. The board of directors of the Company
fully supports the proposed resolutions listed in the Notice of EGM
and recommends that shareholders vote in favor of the resolutions
set out in the Notice of EGM.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a
global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of
vaccines and therapeutic biologics for infectious diseases and
cancer. It has developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections. The Company
operates in China, the United States, Singapore, and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the biopharmaceutical
industry. For more information, please visit
investor.lakeshorebio.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical or current fact
included in this press release are forward-looking statements,
including but not limited to statements regarding the expected
growth of LakeShore Biopharma, the development progress of all
product candidates, the progress and results of all clinical
trials, LakeShore Biopharma's ability to source and retain talent,
and the cash position of LakeShore Biopharma. Forward-looking
statements may be identified by the use of words such as
"estimate," "plan," "project," "potential," "forecast," "intend,"
"will," "expect," "anticipate," "believe," "goal," "seek," "target"
or other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. These
statements are based on various assumptions, whether identified in
this press release, and on the current expectations of LakeShore
Biopharma's management and are not predictions of actual
performance.
LakeShore Biopharma cannot assure you the forward-looking
statements in this press release will be accurate. These
forward-looking statements are subject to a number of risks and
uncertainties, including those included under the heading "Risk
Factors" in the company's Annual Report on Form 20-F filed with the
Securities and Exchange Commission, or SEC, and other risks
described in documents subsequently filed by the company from time
to time with the SEC. There may be additional risks that LakeShore
Biopharma does not presently know or that LakeShore Biopharma
currently believes are immaterial that could also cause actual
results to differ from those contained in the forward-looking
statements. In light of the significant uncertainties in these
forward-looking statements, nothing in this press release should be
regarded as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved. The forward-looking statements in this press release
represent the views of LakeShore Biopharma as of the date of this
press release. Subsequent events and developments may cause those
views to change. However, while LakeShore Biopharma may update
these forward-looking statements in the future, there is no current
intention to do so, except to the extent required by applicable
law. You should, therefore, not rely on these forward-looking
statements as representing the views of LakeShore Biopharma as of
any date subsequent to the date of this press release. Except as
may be required by law, LakeShore Biopharma does not undertake any
duty to update these forward-looking statements.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original
content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-to-hold-an-extraordinary-general-meeting-of-shareholders-on-september-27-2024-302243544.html
SOURCE LakeShore Biopharma Co., Ltd
